Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Am Heart J ; 269: 1-7, 2024 03.
Artículo en Inglés | MEDLINE | ID: mdl-38109984

RESUMEN

BACKGROUND: Previous studies have examined the impact of antithrombotic agents on Patent Foramen Ovale (PFO) in relation to migraine. However, differences in effectiveness of different antithrombotic agents and traditional migraine medications are not known. METHODS/DESIGN: This study is an investigator-initiated, randomized, multicenter, single-masked (outcomes assessor), and active-controlled parallel-group trial (ClinicalTrials.gov Identifier: NCT05546320), with the objective of evaluating the prevention efficacy of antithrombotic agents compared to first-line migraine medication in PFO patients. The trial involves 1,000 migraine patients with a right-to-left shunt at the atrial level, randomized in a 1:1:1:1 fashion to receive either aspirin 300 mg QD, clopidogrel 75 mg QD, rivaroxaban 20 mg QD, or the active-control metoprolol 25 mg BID. The primary efficacy end point is the response rate, defined as a 50% or greater reduction in the average migraine attack days per month or in the average number of migraine attacks per month at 12-week visit compared to baseline. CONCLUSIONS: The COMPETE trial aims to provide valuable insights into the comparative effectiveness of antithrombotic agents and standard migraine therapies in patients with PFO. This study holds the promise of advancing treatment approaches for individuals having migraines associated with PFO, thus addressing an important gap in current migraine management strategies.


Asunto(s)
Foramen Oval Permeable , Trastornos Migrañosos , Humanos , Foramen Oval Permeable/complicaciones , Foramen Oval Permeable/tratamiento farmacológico , Fibrinolíticos , Trastornos Migrañosos/complicaciones , Trastornos Migrañosos/tratamiento farmacológico , Proyectos de Investigación , Resultado del Tratamiento
2.
JAMA Intern Med ; 184(3): 242-251, 2024 Mar 01.
Artículo en Inglés | MEDLINE | ID: mdl-38252426

RESUMEN

Importance: Use of buprenorphine or methadone to treat opioid use disorder is recommended in pregnancy; however, their teratogenic potential is largely unknown. Objective: To compare the risk of congenital malformations following in utero exposure to buprenorphine vs methadone. Design, Setting, and Participants: This population-based cohort study used health care utilization data from publicly insured Medicaid beneficiaries in the US from 2000 to 2018. A total of 13 360 pregnancies with enrollment from 90 days prior to pregnancy start through 1 month after delivery and first trimester use of buprenorphine or methadone were included and linked to infants. Data were analyzed from July to December 2022. Exposure: A pharmacy dispensing of buprenorphine or a code for administration of methadone in the first trimester. Main Outcomes and Measures: Primary outcomes included major malformations overall and malformations previously associated with opioids (any cardiac malformations, ventricular septal defect, secundum atrial septal defect/nonprematurity-related patent foramen ovale, neural tube defects, clubfoot, and oral clefts). Secondary outcomes included other organ system-specific malformations. Risk differences and risk ratios (RRs) were estimated comparing buprenorphine with methadone, adjusting for confounders with propensity score overlap weights. Results: The cohort included 9514 pregnancies with first-trimester buprenorphine exposure (mean [SD] maternal age, 28.4 [4.6] years) and 3846 with methadone exposure (mean [SD] maternal age, 28.8 [4.7] years). The risk of malformations overall was 50.9 (95% CI, 46.5-55.3) per 1000 pregnancies for buprenorphine and 60.6 (95% CI, 53.0-68.1) per 1000 pregnancies for methadone. After confounding adjustment, buprenorphine was associated with a lower risk of malformations compared with methadone (RR, 0.82; 95% CI, 0.69-0.97). Risk was lower with buprenorphine for cardiac malformations (RR, 0.63; 95% CI, 0.47-0.85), including both ventricular septal defect (RR, 0.62; 95% CI, 0.39-0.98) and secundum atrial septal defect/nonprematurity-related patent foramen ovale (RR, 0.54; 95% CI, 0.30-0.97), oral clefts (RR, 0.65; 95% CI, 0.35-1.19), and clubfoot (RR, 0.55; 95% CI, 0.32-0.94). Results for neural tube defects were uncertain given low event counts. In secondary analyses, buprenorphine was associated with a decreased risk of central nervous system, urinary, and limb malformations but a greater risk of gastrointestinal malformations compared with methadone. These findings were consistent in sensitivity and bias analyses. Conclusions and Relevance: In this cohort study, the risk of most malformations previously associated with opioid exposure was lower in buprenorphine-exposed infants compared with methadone-exposed infants, independent of measured confounders. Malformation risk is one factor that informs the individualized patient decision regarding medications for opioid use disorder in pregnancy.


Asunto(s)
Buprenorfina , Pie Equinovaro , Foramen Oval Permeable , Cardiopatías Congénitas , Defectos del Tabique Interventricular , Defectos del Tubo Neural , Trastornos Relacionados con Opioides , Complicaciones del Embarazo , Embarazo , Lactante , Femenino , Humanos , Adulto , Metadona/efectos adversos , Buprenorfina/efectos adversos , Primer Trimestre del Embarazo , Estudios de Cohortes , Pie Equinovaro/complicaciones , Pie Equinovaro/tratamiento farmacológico , Foramen Oval Permeable/complicaciones , Foramen Oval Permeable/tratamiento farmacológico , Complicaciones del Embarazo/tratamiento farmacológico , Trastornos Relacionados con Opioides/tratamiento farmacológico , Analgésicos Opioides/efectos adversos , Cardiopatías Congénitas/inducido químicamente , Cardiopatías Congénitas/epidemiología , Cardiopatías Congénitas/complicaciones , Defectos del Tubo Neural/complicaciones , Defectos del Tubo Neural/tratamiento farmacológico , Defectos del Tabique Interventricular/complicaciones , Defectos del Tabique Interventricular/tratamiento farmacológico
4.
Rev. bras. oftalmol ; 73(5): 308-310, Sep-Oct/2014. tab, graf
Artículo en Inglés | LILACS | ID: lil-741900

RESUMEN

Oclusão da artéria central da retina é uma doença comumente encontrada em pacientes idosos, mas pode também ser vista em crianças e adultos jovens. Nestes, as principais causas são anomalias cardíacas, sendo o forame oval patente o mais observado. O objetivo do trabalho é relatar o caso de um paciente jovem com oclusão da artéria central da retina apresentando persistência de forame oval e, também, salientar a importância de uma propedêutica detalhada nos casos de oclusões vasculares da retina.


Central retinal artery occlusion it’s a disease most encountered in older patients, however it can be seen in children and young persons. In this situation the principal causes are cardiac abnormalities, and the patent foramen ovale is the most observed. The purpose of this study is to report a case of central retinal artery occlusion in a young patient with patent foramen ovale and, also, describe the importance of a detailed management in cases of retinal vascular occlusions.


Asunto(s)
Humanos , Masculino , Adulto , Oclusión de la Arteria Retiniana/diagnóstico , Oclusión de la Arteria Retiniana/etiología , Foramen Oval Permeable/complicaciones , Foramen Oval Permeable/diagnóstico , Disco Óptico/patología , Retina/patología , Angiografía con Fluoresceína , Agudeza Visual , Aspirina/uso terapéutico , Tomografía de Coherencia Óptica , Foramen Oval Permeable/tratamiento farmacológico , Microscopía con Lámpara de Hendidura , Presión Intraocular
5.
Rev. esp. anestesiol. reanim ; 64(9): 522-527, nov. 2017. tab
Artículo en Español | IBECS (España) | ID: ibc-167092

RESUMEN

A pesar de la importancia del manejo hemodinámico en los pacientes sometidos a trasplante hepático, en la actualidad no existe consenso acerca del tipo de monitorización más apropiada a emplear. En este contexto, la ecocardiografía transesofágica puede aportar información muy útil a los profesionales implicados, aunque sus limitaciones impiden que se extienda su uso aún más en la actualidad (AU)


Despite the importance of haemodynamic management in patients undergoing liver transplantation, there is currently no consensus on the most appropriate type of monitoring to use. In this context, transoesophageal echocardiography can provide useful information to professionals, although their use constraints prevent further spread today (AU)


Asunto(s)
Humanos , Ecocardiografía Transesofágica/instrumentación , Trasplante de Hígado/instrumentación , Hemodinámica , Catéteres , Análisis de la Onda del Pulso/instrumentación , Ecocardiografía Transesofágica , Reperfusión/instrumentación , Foramen Oval Permeable/complicaciones , Foramen Oval Permeable/tratamiento farmacológico , Embolia Pulmonar/complicaciones , Hipertensión Portal/tratamiento farmacológico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA